Krystal Biotech Inc (NASDAQ:KRYS) – Cantor Fitzgerald reduced their FY2019 EPS estimates for Krystal Biotech in a research report issued to clients and investors on Wednesday, March 13th. Cantor Fitzgerald analyst E. Piros now anticipates that the company will earn ($1.39) per share for the year, down from their previous estimate of ($1.29). Cantor Fitzgerald has a “Buy” rating and a $34.00 price objective on the stock.

A number of other equities research analysts also recently commented on the company. Cowen started coverage on Krystal Biotech in a research report on Wednesday, December 12th. They issued an “outperform” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of Krystal Biotech in a research report on Tuesday, January 15th. ValuEngine upgraded Krystal Biotech from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Zacks Investment Research upgraded Krystal Biotech from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a research report on Tuesday, January 8th. Finally, Chardan Capital boosted their target price on Krystal Biotech from $50.00 to $57.50 and gave the stock a “buy” rating in a research report on Tuesday, March 12th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $36.90.

NASDAQ:KRYS opened at $21.10 on Friday. The stock has a market capitalization of $304.49 million, a P/E ratio of -21.75 and a beta of 0.55. Krystal Biotech has a 12 month low of $8.91 and a 12 month high of $28.75.

A number of hedge funds have recently modified their holdings of the business. Geode Capital Management LLC raised its position in Krystal Biotech by 66.2% during the fourth quarter. Geode Capital Management LLC now owns 60,603 shares of the company’s stock valued at $1,259,000 after purchasing an additional 24,137 shares during the period. FMR LLC raised its position in Krystal Biotech by 32.1% during the fourth quarter. FMR LLC now owns 1,235,400 shares of the company’s stock valued at $25,672,000 after purchasing an additional 300,000 shares during the period. Great Point Partners LLC purchased a new stake in Krystal Biotech during the fourth quarter valued at approximately $10,226,000. Barclays PLC purchased a new stake in Krystal Biotech during the fourth quarter valued at approximately $777,000. Finally, Sphera Funds Management LTD. purchased a new stake in Krystal Biotech during the fourth quarter valued at approximately $3,629,000. Institutional investors and hedge funds own 43.04% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.

Read More: Municipal Bonds

Earnings History and Estimates for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.